U.S. markets closed

Genocea Biosciences, Inc. (GNCA)

Other OTC - Other OTC Delayed Price. Currency in USD
0.00740.0000 (0.00%)
At close: 03:58PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.0079
Bid0.0000 x 45900
Ask0.0000 x 800
Day's Range0.0011 - 0.0012
52 Week Range0.0002 - 1.4800
Avg. Volume292,154
Market Cap434,997
Beta (5Y Monthly)1.52
PE Ratio (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for GNCA

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    Daily – Vickers Top Insider Picks for 12/01/2022The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.
    Fair Value
    Economic Moat
    2 days agoArgus Research
View more
  • Benzinga

    Genocea Closes Shop, Delists From NASDAQ

    Genocea Biosciences Inc's (NASDAQ: GNCA) board has voted to wind down the company's ongoing operations and terminate the remaining employees except those deemed necessary to complete an orderly wind down. Yesterday, the company delivered formal notice to The Nasdaq Stock Market Inc of its intent to delist voluntarily and its plans to file a Form 25 with the SEC by June 2 to effect the voluntary delisting. The company received a letter that it was not in compliance with the requirement of the Nas

  • Zacks

    Implied Volatility Surging for Genocea (GNCA) Stock Options

    Investors need to pay close attention to Genocea (GNCA) stock based on the movements in the options market lately.

  • Benzinga

    Genocea Biosciences Stock Dives After Early Data From GEN-011 Trial In Pretreated Solid Tumor Patients

    Genocea Biosciences Inc (NASDAQ: GNCA) has shared initial data from Phase 1/2a TiTAN trial OF GEN-011 in patients with refractory solid tumors. The company says that the early results presented at American Association for Cancer Research (AACR) show anti-tumor activity despite the lower intensity regimens and heavily pretreated tumors. Stable disease was seen at the initial Day 57 scan in four of the five patients. While all patients had progressive disease (PD) at their Day 113 scan, three of t